FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:414-416 July 28, 2005 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Van Assche, G. Related Article by Kleinschmidt-DeMasters, B.K. Related Article by Langer-Gould, A. PubMed Citation

In this issue of the Journal, there are reports describing in detail three patients in whom progressive multifocal leukoencephalopathy (PML) developed during treatment with natalizumab, a humanized monoclonal antibody against ₄ integrins.^1,2,3 These patients were among 3000 who had participated in clinical trials of natalizumab for the treatment of multiple sclerosis or Crohn's disease. PML is a deadly opportunistic infection of the central nervous system (CNS) for which there is no specific treatment. It is caused by reactivation of a clinically latent JC polyomavirus infection. This virus infects and destroys oligodendrocytes, leading to multifocal areas of demyelination and associated neurologic dysfunction. . . . [Full Text of this Article]

This article has been cited by other articles:

• Chen, Y., Bord, E., Tompkins, T., Miller, J., Tan, C. S., Kinkel, R. P., Stein, M. C., Viscidi, R. P., Ngo, L. H., Koralnik, I. J. (2009). Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab. NEJM 361: 1067-1074 [Abstract] [Full Text]  
• Soler, D., Chapman, T., Yang, L.-L., Wyant, T., Egan, R., Fedyk, E. R. (2009). The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases. J. Pharmacol. Exp. Ther. 330: 864-875 [Abstract] [Full Text]  
• Bauer, M., Brakebusch, C., Coisne, C., Sixt, M., Wekerle, H., Engelhardt, B., Fassler, R. (2009). {beta}1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc. Natl. Acad. Sci. USA 106: 1920-1925 [Abstract] [Full Text]  
• Nived, O, Bengtsson, A., Jonsen, A, Sturfelt, G (2008). Progressive multifocal leukoencephalopathy - the importance of early diagnosis illustrated in four cases. Lupus 17: 1036-1041 [Abstract]  
• Chalkidou, K., Lord, J., Fischer, A., Littlejohns, P. (2008). Evidence-Based Decision Making: When Should We Wait For More Information?. Health Aff (Millwood) 27: 1642-1653 [Abstract] [Full Text]  
• Krumbholz, M., Meinl, I., Kumpfel, T., Hohlfeld, R., Meinl, E. (2008). Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71: 1350-1354 [Abstract] [Full Text]  
• Kesari, S., Akar, S., Saad, A., Drappatz, J., Koralnik, I. J., DeAngelo, D. J. (2008). Progressive Multifocal Leukoencephalopathy in a Patient With Relapsed Acute Myelogenous Leukemia. JCO 26: 3804-3807 [Full Text]  
• Schrijver, H. M., De Palma, R., Sementa, A., Chaudhuri, A., Behan, P. O., Hauser, S. L., Waubant, E., Bar-Or, A., the HERMES Trial Group, (2008). Rituximab in Relapsing-Remitting Multiple Sclerosis. NEJM 358: 2645-2647 [Full Text]  
• Vollmer, T, Panitch, H, Bar-Or, A, Dunn, J, Freedman, M., Gazda, S., Campagnolo, D, Deutsch, F, Arnold, D. (2008). Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14: 663-670 [Abstract]  
• van Vollenhoven, R. (2008). The Janus of lupus - benefits and risks with B-cell therapy. Lupus 17: 447-449 [Abstract]  
• Koskinen, K., Nevalainen, S., Karikoski, M., Hanninen, A., Jalkanen, S., Salmi, M. (2007). VAP-1-Deficient Mice Display Defects in Mucosal Immunity and Antimicrobial Responses: Implications for Antiadhesive Applications. J. Immunol. 179: 6160-6168 [Abstract] [Full Text]  
• Yang, W, Beaudoin, E., Lu, L, Du Pasquier, R., Kuroda, M., Willemsen, R., Koralnik, I., Junghans, R. (2007). Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). Int Immunol 19: 1083-1093 [Abstract] [Full Text]  
• Lima, M. A., Marzocchetti, A., Autissier, P., Tompkins, T., Chen, Y., Gordon, J., Clifford, D. B., Gandhi, R. T., Venna, N., Berger, J. R., Koralnik, I. J. (2007). Frequency and Phenotype of JC Virus-Specific CD8+ T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy. J. Virol. 81: 3361-3368 [Abstract] [Full Text]  
• Hallenbeck, J., del Zoppo, G., Jacobs, T., Hakim, A., Goldman, S., Utz, U., Hasan, A., for the Immunomodulation Workshop Participants, (2006). Immunomodulation Strategies for Preventing Vascular Disease of the Brain and Heart: Workshop Summary. Stroke 37: 3035-3042 [Abstract] [Full Text]  
• Berger, J R (2006). Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65: iii48-iii53 [Abstract] [Full Text]  
• McFarland, H. F., Jacobson, S. (2006). Natalizumab and immune cells.. Arch Neurol 63: 1366-1367 [Full Text]  
• Eng, P. M., Turnbull, B. R., Cook, S. F., Davidson, J. E., Kurth, T., Seeger, J. D. (2006). Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population.. Neurology 67: 884-886 [Abstract] [Full Text]  
• Poulin, D. L., DeCaprio, J. A. (2006). Is There a Role for SV40 in Human Cancer?. JCO 24: 4356-4365 [Abstract] [Full Text]  
• Gold, R., Linington, C., Lassmann, H. (2006). Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971 [Abstract] [Full Text]  
• Kerfoot, S. M., Norman, M. U., Lapointe, B. M., Bonder, C. S., Zbytnuik, L., Kubes, P. (2006). Reevaluation of P-Selectin and {alpha}4 Integrin as Targets for the Treatment of Experimental Autoimmune Encephalomyelitis. J. Immunol. 176: 6225-6234 [Abstract] [Full Text]  
• Chen, Y., Trofe, J., Gordon, J., Du Pasquier, R. A., Roy-Chaudhury, P., Kuroda, M. J., Woodle, E. S., Khalili, K., Koralnik, I. J. (2006). Interplay of Cellular and Humoral Immune Responses against BK Virus in Kidney Transplant Recipients with Polyomavirus Nephropathy. J. Virol. 80: 3495-3505 [Abstract] [Full Text]  
• Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Sandrock, A. W., the SENTINEL Investigators, (2006). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.. NEJM 354: 911-923 [Abstract] [Full Text]  
• Ropper, A. H. (2006). Selective treatment of multiple sclerosis.. NEJM 354: 965-967 [Full Text]  
• Garrood, T., Lee, L., Pitzalis, C. (2006). Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways. Rheumatology (Oxford) 45: 250-260 [Full Text]  
• Chaudhuri, A. (2006). Lessons for clinical trials from natalizumab in multiple sclerosis.. BMJ 332: 416-419 [Full Text]  
• Lima, M. A., Drislane, F. W., Koralnik, I. J. (2006). Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66: 262-264 [Abstract] [Full Text]  
• Mahad, D., Callahan, M. K., Williams, K. A., Ubogu, E. E., Kivisakk, P., Tucky, B., Kidd, G., Kingsbury, G. A., Chang, A., Fox, R. J., Mack, M., Sniderman, M. B., Ravid, R., Staugaitis, S. M., Stins, M. F., Ransohoff, R. M. (2006). Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129: 212-223 [Abstract] [Full Text]  
• Keeley, K. A, Rivey, M. P, Allington, D. R (2005). Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. The Annals of Pharmacotherapy 39: 1833-1843 [Abstract] [Full Text]  
• Danese, S., De La Rue, S. A., Gasbarrini, A., Feagan, B. G., Fox, I. H., Kishimoto, K. (2005). Antibody to {alpha}4{beta}7 Integrin for Ulcerative Colitis. NEJM 353: 1180-1181 [Full Text]  
• Drazen, J. M. (2005). Patients at Risk. NEJM 353: 417-417 [Full Text]